FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
American Oriental Bioengineering, Inc. Stock AnalysisComprehensive stock analysis for American Oriental Bioengineering, Inc. (AOBI) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAOBI
AOBI
American Oriental Bioengineering, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
AOBI
Home🔹Stocks🔹American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc.

🇺🇸AOBI•OTC

American Oriental Bioengineering, Inc.

🇺🇸AOBI•OTC
Market cap
$88
Sentiment

Your view on AOBI

Mkt Cap
$88
Sentiment
Your view
AOBI
American Oriental Bioengineering, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
AOBI
Company Overview

Overview

What the company does, where it operates, and who runs it.

About American Oriental Bioengineering, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Shujun Liu
Headquarters
1 First Liangshuihe Avenue, Beijing, CN
Industry
Biotechnology
Sector
Healthcare
CEO
Shujun Liu
Headquarters
1 First Liangshuihe Avenue, Beijing, CN
Description

American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products.

The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting.

It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis.

In addition, the company provides various nutraceutical products, such as soybean peptide based drinks, tablets, powder, and instant coffee. Further, it is involved in the wholesale and retail of pharmaceutical and nutraceutical products.

The company sells its products directly and through distributors to hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical stores, and other retail outlets in the People's Republic of China. American Oriental Bioengineering, Inc. is headquartered in Beijing, China.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for American Oriental Bioengineering, Inc., and the rating behind it. AOBI last traded at $0.0012; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for American Oriental Bioengineering, Inc.. Starting points for American Oriental Bioengineering, Inc.: EPS -$781.08, beta 0.14 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for American Oriental Bioengineering, Inc.. American Oriental Bioengineering, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for American Oriental Bioengineering, Inc.. Trailing twelve-month EPS for American Oriental Bioengineering, Inc. stands at -$781.08. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for American Oriental Bioengineering, Inc.. American Oriental Bioengineering, Inc. has reported as a listed company since 2001. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

American Oriental Bioengineering, Inc. valued side by side against its closest peers. American Oriental Bioengineering, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold American Oriental Bioengineering, Inc., and how their positions are changing. At a $88 market value, institutional positions materially move American Oriental Bioengineering, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by American Oriental Bioengineering, Inc. executives and directors. Shares of American Oriental Bioengineering, Inc. have traded between $0.0005 and $0.0012 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming American Oriental Bioengineering, Inc.. American Oriental Bioengineering, Inc. is a $88 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming American Oriental Bioengineering, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for American Oriental Bioengineering, Inc.. Coverage tracks American Oriental Bioengineering, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • ACUS — Acusphere, Inc.
  • CDXI — Cardax, Inc.
  • ENCW — Enchanted World Inc.
  • LGBI — Cannabiz Mobile, Inc.
  • MYMX — Mymetics Corporation
  • NEXI — NexImmune, Inc.
  • PARD — Poniard Pharmaceuticals, Inc.

More Biotechnology companies

  • ELUT — Elutia Inc.
  • ELVN — Enliven Therapeutics, Inc.
  • EMMA — Emmaus Life Sciences, Inc.
  • ENDV — Endonovo Therapeutics, Inc.
  • ENGN — enGene Holdings Inc.
  • ENGNW — enGene Holdings Inc. Warrants
  • ENLV — Enlivex Therapeutics Ltd.
  • ENP.AX — Entropy Neurodynamics Limited
  • ENSC — Ensysce Biosciences, Inc.
  • ENTA — Enanta Pharmaceuticals, Inc.
  • ENTX — Entera Bio Ltd.
  • ENVB — Enveric Biosciences, Inc.

News

Latest Market News